GB202306060D0 - Antisense oligonucleotides for the treatment of hereditary hfe-hemochromatosis - Google Patents
Antisense oligonucleotides for the treatment of hereditary hfe-hemochromatosisInfo
- Publication number
- GB202306060D0 GB202306060D0 GBGB2306060.1A GB202306060A GB202306060D0 GB 202306060 D0 GB202306060 D0 GB 202306060D0 GB 202306060 A GB202306060 A GB 202306060A GB 202306060 D0 GB202306060 D0 GB 202306060D0
- Authority
- GB
- United Kingdom
- Prior art keywords
- hemochromatosis
- hfe
- hereditary
- treatment
- antisense oligonucleotides
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 108020000948 Antisense Oligonucleotides Proteins 0.000 title 1
- 208000018565 Hemochromatosis Diseases 0.000 title 1
- 239000000074 antisense oligonucleotide Substances 0.000 title 1
- 238000012230 antisense oligonucleotides Methods 0.000 title 1
Priority Applications (10)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB2306060.1A GB202306060D0 (en) | 2023-04-25 | 2023-04-25 | Antisense oligonucleotides for the treatment of hereditary hfe-hemochromatosis |
| JP2025530405A JP2025536808A (en) | 2022-11-24 | 2023-11-23 | Antisense oligonucleotides for the treatment of hereditary hfe hemochromatosis |
| ARP230103153A AR131145A1 (en) | 2022-11-24 | 2023-11-23 | Antisense oligonucleotides for the treatment of hereditary hemochromatosis (HFE) |
| TW112145333A TW202435897A (en) | 2022-11-24 | 2023-11-23 | Antisense oligonucleotides for the treatment of hereditary hfe-hemochromatosis |
| PCT/EP2023/082797 WO2024110565A1 (en) | 2022-11-24 | 2023-11-23 | Antisense oligonucleotides for the treatment of hereditary hfe-hemochromatosis |
| KR1020257020431A KR20250113455A (en) | 2022-11-24 | 2023-11-23 | Antisense oligonucleotides for the treatment of hereditary hemochromatosis-HFE |
| AU2023385245A AU2023385245A1 (en) | 2022-11-24 | 2023-11-23 | Antisense oligonucleotides for the treatment of hereditary hfe-hemochromatosis |
| EP23822239.2A EP4623084A1 (en) | 2022-11-24 | 2023-11-23 | Antisense oligonucleotides for the treatment of hereditary hfe-hemochromatosis |
| CN202380090733.6A CN120476207A (en) | 2022-11-24 | 2023-11-23 | Antisense oligonucleotides for the treatment of hereditary HFE hemochromatosis |
| MX2025005934A MX2025005934A (en) | 2022-11-24 | 2025-05-21 | Antisense oligonucleotides for the treatment of hereditary hfe-hemochromatosis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB2306060.1A GB202306060D0 (en) | 2023-04-25 | 2023-04-25 | Antisense oligonucleotides for the treatment of hereditary hfe-hemochromatosis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| GB202306060D0 true GB202306060D0 (en) | 2023-06-07 |
Family
ID=86605519
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GBGB2306060.1A Ceased GB202306060D0 (en) | 2022-11-24 | 2023-04-25 | Antisense oligonucleotides for the treatment of hereditary hfe-hemochromatosis |
Country Status (1)
| Country | Link |
|---|---|
| GB (1) | GB202306060D0 (en) |
-
2023
- 2023-04-25 GB GBGB2306060.1A patent/GB202306060D0/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL309445A (en) | Pikfyve antisense oligonucleotides | |
| IL286872A (en) | Antisense oligonucleotides for the treatment of usher syndrome | |
| IL304751A (en) | Process for the de-tritylation of oligonucleotides | |
| IL315749A (en) | Modified oligonucleotides | |
| IL284417A (en) | Antisense oligonucleotides for the treatment of leber's congenital amaurosis | |
| GB202306060D0 (en) | Antisense oligonucleotides for the treatment of hereditary hfe-hemochromatosis | |
| GB202217580D0 (en) | Antisense oligonucleotides for the treatment of hereditary hfe-hemochromatosis | |
| AU2024246572A1 (en) | Antisense oligonucleotides for the treatment of liver disease | |
| AU2023390632A1 (en) | Antisense oligonucleotides for the treatment of cardiovascular disease | |
| CA3272746A1 (en) | Antisense oligonucleotides for the treatment of hereditary hfe-hemochromatosis | |
| GB202502460D0 (en) | Antisense oligonucleotides for the treatment of cancer | |
| GB202400404D0 (en) | Antisense oligonucleotides for the treatment of polg-related disorders | |
| GB202416174D0 (en) | Antisense oligonucleotides for the treatment of migraine | |
| GB202418430D0 (en) | Antisense oligonucleotides for the treatment of migrane | |
| GB202318087D0 (en) | Antisense oligonucleotides for the treatment of liver disease | |
| GB202304438D0 (en) | Antisense oligonucleotides for the treatment of liver disease | |
| GB202508058D0 (en) | Antisense oligonucleotides for the treatment of renal disorders | |
| GB202502057D0 (en) | Antisense oligonucleotides for the treatment of renal disorders | |
| GB202502170D0 (en) | Antisense oligonucleotides for the treatment of disease | |
| GB202417404D0 (en) | Antisense oligonucleotides for the treatment of kidney disorders | |
| GB202306756D0 (en) | Antisense oligonucleotides for the treatment of cardiovascular disease | |
| GB202218585D0 (en) | Antisense oligonucleotides for the treatment of cardiovascular disease | |
| CA3294368A1 (en) | Antisense oligonucleotides for the treatment of neurodegenerative disease | |
| GB202502332D0 (en) | Antisense oligonucleotides for the treatment of liver cancer | |
| GB202502189D0 (en) | Antisense oligonucleotides for the treatment of liver cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AT | Applications terminated before publication under section 16(1) |